Overview of the drug development pipeline for Friedreich’s ataxia
It has been observed that Friedreich’s ataxia is defined as a rare genetic disease caused by a defect (mutation) in a gene labeled FXN, which carries the genetic code for a protein called frataxin. Friedreich’s ataxia usually starts in childhood, and it worsens over a period. This also leads to impairments in muscle coordination. People with Friedreich’s ataxia can also have a form of hypertrophic cardiomyopathy, which enlarges and weakens the heart muscle. Some of the key symptoms of the disease include difficulty in walking and poor balance, shortness of breath, and loss of normal reflexes, especially for knees and ankles. Consequently, the rising incidences of Friedreich’s ataxia are expected to boost the drug development for Friedreich’s ataxia over the predicted period.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for Friedreich’s ataxia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of Friedreich’s ataxia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Adverum
- Agilis Biotherapeutics
- Bioblast Pharma
- Cardero Therapeutics
- Chondrial Therapeutics
Therapeutic assessment of the drug development pipeline for Friedreich’s ataxia by route of administration
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for Friedreich’s ataxia by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for Friedreich’s ataxia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for Friedreich’s ataxia?
- What are the companies that are currently involved in the development of drug molecules for Friedreich’s ataxia?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape